The stock of Traws Pharma Inc (TRAW) has gone down by -18.12% for the week, with a -39.00% drop in the past month and a -82.09% drop in the past quarter. The volatility ratio for the week is 17.04%, and the volatility levels for the past 30 days are 14.11% for TRAW. The simple moving average for the past 20 days is -21.29% for TRAW’s stock, with a -78.19% simple moving average for the past 200 days.
Is It Worth Investing in Traws Pharma Inc (NASDAQ: TRAW) Right Now?
The 36-month beta value for TRAW is at 1.21. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TRAW is 3.94M, and currently, shorts hold a 1.88% of that float. The average trading volume for TRAW on May 14, 2025 was 81.81K shares.
TRAW) stock’s latest price update
The stock price of Traws Pharma Inc (NASDAQ: TRAW) has dropped by -12.23 compared to previous close of 1.39. Despite this, the company has seen a fall of -18.12% in its stock price over the last five trading days. seekingalpha.com reported 2025-04-01 that Traws Pharma, Inc. (NASDAQ:TRAW ) Virtual Investor Event March 31, 2025 10:00 AM ET Company Participants Werner Cautreels – Chief Executive Officer Robert Redfield – Chief Medical Officer David Pauza – Chief Science Officer-Virology Iain Dukes – Executive Chairman Bruce Mackle – LifeSci Advisors Conference Call Participants Operator Good morning, and welcome to the Traws Pharma Investor Call on Bird Flu and COVID and Traws Innovative Small Molecule Product Candidates. At this time all attendees are in a listen-only mode.
Analysts’ Opinion of TRAW
Many brokerage firms have already submitted their reports for TRAW stocks, with Ladenburg Thalmann repeating the rating for TRAW by listing it as a “Buy.” The predicted price for TRAW in the upcoming period, according to Ladenburg Thalmann is $7 based on the research report published on March 01, 2022 of the previous year 2022.
Guggenheim, on the other hand, stated in their research note that they expect to see TRAW reach a price target of $4. The rating they have provided for TRAW stocks is “Buy” according to the report published on May 18th, 2021.
H.C. Wainwright gave a rating of “Buy” to TRAW, setting the target price at $7.50 in the report published on March 01st of the previous year.
TRAW Trading at -41.65% from the 50-Day Moving Average
After a stumble in the market that brought TRAW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.72% of loss for the given period.
Volatility was left at 14.11%, however, over the last 30 days, the volatility rate increased by 17.04%, as shares sank -42.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.72% lower at present.
During the last 5 trading sessions, TRAW fell by -18.12%, which changed the moving average for the period of 200-days by -88.02% in comparison to the 20-day moving average, which settled at $1.5500. In addition, Traws Pharma Inc saw -86.26% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TRAW
Current profitability levels for the company are sitting at:
- -110.22 for the present operating margin
- 0.96 for the gross margin
The net margin for Traws Pharma Inc stands at -736.83. The total capital return value is set at -1.85. Equity return is now at value -2255.45, with -229.51 for asset returns.
Currently, EBITDA for the company is -24.9 million with net debt to EBITDA at 0.86. When we switch over and look at the enterprise to sales, we see a ratio of -65.62. The receivables turnover for the company is 0.13for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.16.
Conclusion
In conclusion, Traws Pharma Inc (TRAW) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
